<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629889</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000586523</org_study_id>
    <secondary_id>CHUV-Neurology-CePO-LEV-PGB</secondary_id>
    <secondary_id>EU-20807</secondary_id>
    <nct_id>NCT00629889</nct_id>
  </id_info>
  <brief_title>Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors</brief_title>
  <official_title>Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Andrea Rossetti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Levetiracetam and pregabalin are drugs that treat seizures. It is not yet known
      which drug is more effective in treating seizures caused by primary brain tumors.

      PURPOSE: This randomized phase II trial is studying the side effects and how well
      levetiracetam or pregabalin work in treating seizures in patients undergoing chemotherapy
      and/or radiation therapy for primary brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the safety and efficacy of antiepileptic drug monotherapy comprising
           levetiracetam or pregabalin in treating seizures in patients undergoing chemotherapy
           and/or radiotherapy for primary brain tumors.

      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive levetiracetam.

        -  Arm II: Patients receive pregabalin. Patients are followed at 2 weeks, 2 months, 6
           months, and then at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without occurrence of status epilepticus, 2 seizures with consciousness impairment, need to add a second antiepileptic drug (AED) (except transitory benzodiazepine), and need to discontinue study drug for lack of efficacy or adverse events</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need to add a second AED</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study drug discontinuation</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of consciousness-impairing seizures or status epilepticus</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>baseline to visit at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Seizure</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.
Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.</description>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.
Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.</description>
    <arm_group_label>Levetiracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of primary brain tumor

               -  WHO grade II-IV disease

          -  Undergoing chemotherapy and/or radiotherapy

          -  No brain tumor without the potential need for chemotherapy (e.g., meningioma without
             anaplastic features)

          -  Has had at least one seizure provoked by the brain tumor, justifying introduction of
             antiepileptic drug (AED) treatment

               -  No status epilepticus

        PATIENT CHARACTERISTICS:

          -  Modified Rankin score &lt; 4 at study enrollment

          -  Life expectancy ≥ 4 weeks

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known intolerance to the study drugs

          -  No pre-existing psychosis and/or current suicidality

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No concurrent IV AEDs other than benzodiazepines

          -  Other concurrent AEDs, except phenobarbital, allowed provided they are discontinued
             within 2 weeks after study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea O. Rossetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USZ</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>May 21, 2013</last_update_submitted>
  <last_update_submitted_qc>May 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Dr Andrea Rossetti</investigator_full_name>
    <investigator_title>Médecin associé</investigator_title>
  </responsible_party>
  <keyword>seizure</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic meningioma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult papillary meningioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult grade II meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

